3 results about "Very low-density lipoprotein" patented technology

The invention relates to the technical field of biological medicines, in particular to a Chinese wolfberry all-component mixture and application thereof in treatment of diabetes mellitus. The Chinese wolfberry all-component mixture is prepared through the following steps: S1, taking Chinese wolfberry fruits, performing continuous extraction for three times, combining extracting solutions obtained by the three times of extraction, performing filtration, and performing concentration so as to obtain a Chinese wolfberry fruit extract; s2, taking leaf buds, carpopodium and branches of the Chinese wolfberry, performing continuous extraction for three times, combining the three extraction solutions, filtering, and concentrating to obtain a leaf bud / carpopodium / branch extract of the Chinese wolfberry; and S3, mixing the Chinese wolfberry fruit extract obtained in the step S1 with the Chinese wolfberry leaf bud / fruit stem / branch extract obtained in the step S2, filtering, performing graded purification by adopting an ultrafiltration method, intercepting 20-100kDa components, and sterilizing to obtain a Chinese wolfberry all-component mixture. The Chinese wolfberry all-component mixture disclosed by the invention can be used for remarkably reducing a plurality of biochemical index levels such as fasting blood-glucose, glycosylated hemoglobin, triglyceride and extremely low density lipoprotein of a mouse with type 2 diabetes mellitus.

The invention relates to a compound 7-3A for reducing blood fat and application of the compound 7-3A. The structure of the compound 7-3A is shown as a formula (1). Formula (1). The invention also relates to the following application of the compound as shown in the formula (1): (1) preparing a medicine or preparation for controlling and / or reducing the body weight of a hyperlipidemia patient; (2) preparing medicines or preparations for controlling and / or reducing the serum triglyceride (TG) level of hyperlipidemia patients; and (3) preparing a medicine or a preparation for inhibiting very low density lipoprotein (VLDL) of hyperlipidemia patients from transferring endogenous triglyceride.

This invention discloses the application of FGA protein in improving egg production in chickens, belonging to the field of genetic engineering technology. Experiments have demonstrated that the FGA gene has a significant effect on improving egg production in chickens. Experimental results show that overexpression of the FGA gene can significantly increase the levels of reproductive hormones such as follicle-stimulating hormone, luteinizing hormone, estradiol, and progesterone in chicken serum, while significantly reducing prolactin concentration. Regarding follicle development, it can significantly increase the number of small yellow follicles, reduce the number of small white follicles, and promote follicle maturation. Regarding lipid metabolism regulation, it can significantly increase the concentrations of cholesterol, triglycerides, and very low-density lipoprotein in serum. This invention reveals for the first time the molecular mechanism by which the liver-specific endocrine factor FGA regulates egg production in chickens through interstitial communication, providing a new molecular target and application strategy for improving egg production in local chicken breeds.